Premium
Structural improvement of new thiazolidinones compounds with antinociceptive activity in experimental chemotherapy‐induced painful neuropathy
Author(s) -
Moreira Diogo Rodrigo Magalhaes,
Santos Dourivaldo Silva,
Espírito Santo Renan Fernandes do,
Santos Flávia Evangelista dos,
Oliveira Filho Gevanio Bezerra,
Leite Ana Cristina Lima,
Soares Milena Botelho Pereira,
Villarreal Cristiane Flora
Publication year - 2017
Publication title -
chemical biology and drug design
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.59
H-Index - 77
eISSN - 1747-0285
pISSN - 1747-0277
DOI - 10.1111/cbdd.12951
Subject(s) - neuropathic pain , gabapentin , nociception , analgesic , pharmacology , medicine , drug , chemotherapy , antagonist , chemistry , receptor , alternative medicine , pathology
Chemotherapy‐induced neuropathy is a disabling pain condition resulting from chemotherapy for cancers. Up to now, no drug is available to cure chemotherapy‐induced neuropathy. In the present study, we describe the structural design, synthesis, chemical and pharmacological characterization of 15 thiazolidinones, a class of potential analgesic compounds. The synthesis of new thiazolidinones was achieved by using the thiazolidinone heterocyclic as main structural pharmacophoric group and varying the substituents attached to the phenyl near to the iminic bond. The analgesic potential of the compounds was investigated in a mice model of oxaliplatin‐induced neuropathic pain, using von Frey, rota‐rod and open‐field tests. Except for compound 14 , these thiazolidinones exhibited antinociceptive property without causing motor impairment. Thiazolidinones 12 , 15 and 16 displayed a dose‐dependent antinociceptive effect, with similar efficacy and enhanced potency than gabapentin, the gold standard drug used for neuropathic pain. In addition, the antinociceptive activity of 16 lasted longer than gabapentin. The antinociceptive effect of thiazolidinones was prevented by GW9662, a PPARγ antagonist. The main antinociceptive compounds exhibited positive Lipinski's index, predicting their oral bioavailability. In conclusion, the structural design performed here led to the identification of new compounds endowed with potent antinociceptive activity, potentially useful to treat chemotherapy‐induced neuropathic pain.